![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TT-00420 (Tinengotinib), a next-generation FGFR inhibitor with high potency against a variety of FGFR2 kinase domain mutations, has shown promising clinical benefit in subjects with FGFR-altered metastatic CCA.
Lead Product(s): TT-00420
Therapeutic Area: Oncology Product Name: TT-00420
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
TT-00420 (tinengotinib), which is an investigational next-generation FGFR inhibitor. currently, it is being evaluated in the Phase III clinical trial studies with patients for the treatment of advanced FGFR-altered cholangiocarcinoma.
Lead Product(s): TT-00420
Therapeutic Area: Oncology Product Name: TT-00420
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
TT-00420 is spectrum selective kinase inhibitor that is found to show high potency to a variety of clinically identified FGFR2 mutations in preclinical experiments. A large number of preclinical studies have found that TT-00420 has promising inhibitory effect on tumors.
Lead Product(s): TT-00420
Therapeutic Area: Oncology Product Name: TT-00420
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021